We are live on ! Find out more
GILD icon

Gilead Sciences

1,438 hedge funds and large institutions have $120B invested in Gilead Sciences in 2014 Q4 according to their latest regulatory filings, with 216 funds opening new positions, 604 increasing their positions, 518 reducing their positions, and 90 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 216 | Existing positions closed: 90

17% more repeat investments, than reductions

Existing positions increased: 604 | Existing positions reduced: 518

8% more funds holding

Funds holding: 1,3261,438 (+112)

13% less capital invested

Capital invested by funds: $139B → $120B (-$18.6B)

18% less funds holding in top 10

Funds holding in top 10: 240196 (-44)

32% less call options, than puts

Call options by funds: $3.07B | Put options by funds: $4.55B

Holders
1,438
Holders Change
+112
Holders Change %
+8.45%
% of All Funds
38.35%
Holding in Top 10
196
Holding in Top 10 Change
-44
Holding in Top 10 Change %
-18.33%
% of All Funds
5.23%
New
216
Increased
604
Reduced
518
Closed
90
Calls
$3.07B
Puts
$4.55B
Net Calls
-$1.48B
Net Calls Change
-$53.3M
Name Holding Trade Value Shares
Change
Change in
Stake
CWG
51
C WorldWide Group
Denmark
$410M -$24.1M -233,328 -5%
BlackRock
52
BlackRock
New York
$404M +$2.46M +23,827 +0.6%
FAM
53
Fred Alger Management
New York
$402M +$5.59M +54,075 +1%
O
54
OrbiMed
New York
$401M +$50.4M +487,300 +13%
CCI
55
Columbus Circle Investors
$393M +$5.08M +49,163 +1%
Swedbank
56
Swedbank
Sweden
$379M +$416M +4,019,416 New
Sumitomo Mitsui Trust Group
57
Sumitomo Mitsui Trust Group
Japan
$377M -$8.62M -83,343 -2%
Axa
58
Axa
France
$367M +$22M +212,919 +6%
Parnassus Investments
59
Parnassus Investments
California
$364M +$51.1M +494,529 +15%
CGT
60
Capital Guardian Trust
California
$354M -$168M -1,621,639 -30%
VOYA Investment Management
61
VOYA Investment Management
Georgia
$353M +$7.48M +72,349 +2%
MC
62
Montag & Caldwell
Georgia
$348M -$97.5M -942,387 -20%
BNP Paribas Financial Markets
63
BNP Paribas Financial Markets
France
$345M +$30M +289,658 +9%
BIM
64
BlackRock Investment Management
Delaware
$337M +$5.17M +49,976 +1%
AIM
65
abrdn Investment Management
United Kingdom
$332M -$3.66M -35,382 -1%
Prudential Financial
66
Prudential Financial
New Jersey
$326M +$431K +4,170 +0.1%
EVM
67
Eaton Vance Management
Massachusetts
$321M -$73.9M -714,674 -17%
Barclays
68
Barclays
United Kingdom
$312M -$26M -251,624 -7%
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
$301M +$49.2M +475,440 +17%
AAMU
70
Amundi Asset Management US
Massachusetts
$300M -$36.7M -355,075 -10%
Principal Financial Group
71
Principal Financial Group
Iowa
$285M +$19.8M +191,409 +7%
New York State Teachers Retirement System (NYSTRS)
72
New York State Teachers Retirement System (NYSTRS)
New York
$283M -$4.92M -47,584 -2%
Mitsubishi UFJ Trust & Banking
73
Mitsubishi UFJ Trust & Banking
Japan
$282M +$1.93M +18,682 +0.6%
BB
74
BB Biotech
Switzerland
$278M +$15.5M +150,000 +5%
TIM
75
Thornburg Investment Management
New Mexico
$273M -$62.9M -608,190 -17%

GILD Hedge Fund Activity: Q4 2014 in Review

1,438 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q4 2014, worth a combined $120B — down 13% from $139B a quarter earlier.

Buyers outnumbered sellers: 216 funds opened new GILD positions and 90 closed out — a net gain of 126 holders — while 604 added to existing stakes and 518 trimmed.

The largest buyer was Temasek Holdings, adding an estimated $811M. The largest seller was Capital Research Global Investors, cutting an estimated $2.53B.

  • 1,438 institutional investors held Gilead Sciences (GILD) as of Q4 2014, up from 1,326 in Q3 2014.
  • Funds reported $120B of Gilead Sciences stock for Q4 2014, down 13% quarter-over-quarter.
  • 216 funds opened new Gilead Sciences positions in Q4 2014 and 90 closed out, a net change of +126 holders.
  • The largest Gilead Sciences buyer in Q4 2014 was Temasek Holdings, an estimated $811M added.
  • The largest Gilead Sciences seller in Q4 2014 was Capital Research Global Investors, an estimated $2.53B sold.

Based on aggregated 13F filings for Q4 2014.